Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Payables (2021 - 2025)

Prime Medicine's Payables history spans 5 years, with the latest figure at $8.9 million for Q4 2025.

  • For Q4 2025, Payables fell 21.71% year-over-year to $8.9 million; the TTM value through Dec 2025 reached $8.9 million, down 21.71%, while the annual FY2025 figure was $8.9 million, 21.71% down from the prior year.
  • Payables reached $8.9 million in Q4 2025 per PRME's latest filing, down from $9.4 million in the prior quarter.
  • In the past five years, Payables ranged from a high of $19.5 million in Q4 2023 to a low of $1.4 million in Q4 2021.
  • Average Payables over 5 years is $8.0 million, with a median of $6.4 million recorded in 2025.
  • Peak YoY movement for Payables: skyrocketed 350.99% in 2023, then plummeted 61.56% in 2024.
  • A 5-year view of Payables shows it stood at $1.4 million in 2021, then surged by 201.88% to $4.3 million in 2022, then surged by 350.99% to $19.5 million in 2023, then plummeted by 41.9% to $11.4 million in 2024, then fell by 21.71% to $8.9 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's Payables are $8.9 million (Q4 2025), $9.4 million (Q3 2025), and $6.4 million (Q2 2025).